AACR Annual Meeting 2023

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings during AACR 2023.

Schedule a meeting with us

Tempus Customer Reception

Thank you for your interest in our event. The event has concluded, and we are no longer accepting RSVP submissions. To explore more about Tempus and to keep the conversation going, please take a moment to share a bit more about what you are interested in. We will connect you with the right team member.

Tempus Exhibitor Spotlight Theater
Poster Highlights

Tempus Exhibitor Spotlight Theater

April 17, 2023

live session

Time
10:00AM EDT

Kate Sasser, PhD | Chief Scientific Officer, Tempus

Anne-Marie Martin, PhD; SVP & Global Head of Experimental Medicine Unit, GSK

Delivering on the Promise of Precision Medicine: Leveraging Diagnostics and Data to Drive Next-Generation Drug Development

Precision medicine is making progress today with the convergence of richer data sets, next-generation sequencing and modeling technologies, and advanced AI/ ML methodologies. To fully realize this potential, precision medicine needs 1) “smart” diagnostics, 2) tailored therapies, and 3) appropriate timing of interventions. Each of these is challenging, but developing effective therapeutics faces the specific hurdles of increasing complexity, competition, and costs. Tempus is focused on leveraging its capabilities to help biopharma partners bring personalized medicines to patients as fast as possible in this complex environment -- in this conversation, we discuss how tools like multimodal real world data and advanced machine learning/ AI methodologies are powering next-generation drug development and driving precision medicine forward.

Poster Highlights

April 17, 2023

Poster #CT055 / Poster Board #13

Time
09:00am – 12:30pm CDT

First Author
Tian Zhang; UT Southwestern

PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors

PARP inhibitors have demonstrated efficacy in treating solid tumors with Homologous Recombination Deficiency, the inability to repair DNA double-stranded breaks through the Homologous Recombination Repair (HRR) pathway. While BRCA1/2 are instrumental to HRR, multiple genes, including PALB2, impact the HRR pathway. No clinically approved therapies specifically targeting PALB2 currently exist, however emerging evidence suggests that patients with germline or somatic PALB2 mutations may benefit from PARP inhibitor treatment. Tempus molecular data tracking (integrated NGS and EMR data) and the TIME Trial program (rapid match of patients to Just in TIME sites for clinical trials), enabled patient identification and prescreening for this trial.

Poster #3148

Time
01:30pm – 5:00pm CDT

First Author
Joshua Drews; Tempus

Leveraging scale in precision oncology to measure pathway activation and detect genetic drivers in a large, real-world pan-cancer cohort

Cancer tumorigenesis and progression are driven by genetic and epigenetic alterations, giving rise to transcriptional and pathway dysregulation. The Tempus team developed a machine learning platform that integrates DNA alterations and RNA expression data to measure the activation states of oncogenic signaling pathways and characterize novel genetic alterations that may cause pathway dysregulation, and tested it on Tempus’ multimodal real-world database. Assessing both the level of pathway disruption and underlying genomic drivers may provide a more comprehensive understanding of tumor biology than assessing either factor alone.

April 18, 2023

Abstract #5583 / Poster Board #7

Time
01:30pm – 5:00pm CDT

First Author
Nicholas P. Semenkovich; Washington University

Pre-radiotherapy ctDNA risk-stratifies non-small cell lung cancer patients with oligometastatic disease

Widespread metastatic non-small cell lung cancer is difficult to treat, yet some patients with oligometastatic disease experience prolonged progression-free survival when treated with aggressive local stereotactic body radiotherapy (RT). The research team investigated if pre-radiotherapy ctDNA testing can be used to risk-stratify those with oligometastatic NSCLC and enable earlier personalized approaches when considering systemic therapy versus aggressive local RT.

Abstract #4692 / Poster Board #5

Time
01:30pm – 5:00pm CDT

First Author
Mario Rosasco; Tempus

Comparison of interassay similarity and cellular deconvolution in spatial transcriptomics data using Visum CytAssist

While NGS is a useful tool it can’t ascribe the cellular context for a given gene’s expression or elucidate the spatial organization of tumor microenvironments. These additional features are critical to our understanding of tumor biology and are key to the development of immuno-oncology therapeutics. The research team used the CytAssist platform to generate spatial transcriptomic data from patient samples, and used this information to create super resolution spatial transcriptomic maps.

Abstract #5402 / Poster Board #18

Time
01:30pm – 5:00pm CDT

First Author
Madhavi Kannan; Tempus

Using computer vision to resolve proliferative dynamics within therapeutic responses in large-scale screens of patient-derived models

Traditional metrics used to assess in vitro susceptibility for a given therapeutic candidate such as IC50, Emax, and AUC values do not account for cell proliferation rates, which can differ substantially when comparing multiple in vitro patient derived models. The Tempus team developed a computer vision model that utilizes label-free longitudinal light microscopy to report the number of nuclei present in organoid models across multiple cancer types, allowing for the incorporation of cell division and cytostatic effects in drug response.

Schedule a meeting with us

We'll be in touch shortly.